TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01637584
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
Study: NCT02988726
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adults with a recurrent/residual Neurofibroma or Schwannoma will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT03536325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo on Day 1.
Study: NCT01721486
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen 15 mg/kg (up to 1000 mg) over 15 minute infusion after IV placement in OR .
Study: NCT01721486
Drug: PO acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO acetaminophen elixir 15 mg/kg (up to 1000 mg) administered approximately 90 minutes (+/- 30minutes) prior to induction of anesthesia in the pre-operative area.
Study: NCT02030769
Drug: Pronase
Normalized name: Pronase enzyme B
Approvals — FDA: no, EMA: no, PMDA: no
Description: use pronase to improve visibility during endoscopical iodine staining
Study: NCT01501890
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl
Study: NCT04149171
Drug: conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard treatment based on crystalloid fluid and tranexamic acid (TXA)
Study: NCT02812238
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule daily for a period of 7 days in a double blinded fashion either from the start of tx or after 1 week of NR at a dose of 1000mg/day.
Study: NCT00000553
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000553
Drug: antioxidants
Normalized name: E Complex with Antioxidants
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02534883
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: To be placed vaginally
Study: NCT01223339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets to Ertugliflozin administered in the fasted state
Study: NCT01223339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets administered once daily in the fed state for 7 days
Study: NCT04303429
Drug: FOLFOX/XELOX/Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients enrolled in the chemotherapy group will receive postoperative chemotherapy (investigator's choice) for 3 months or 6 months.
Study: NCT01704508
Drug: Artemether-lumefantrine
Normalized name: artemether-lumefantrine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03135912
Drug: Experimental Drug SESC 01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical experimental treatment comprising a combination of approved topical therapies and a new dosage method.
Study: NCT03135912
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage method of SESC 01, without active ingredients.
Study: NCT00092144
Drug: Comparator: placebo / Duration of Treatment: 4 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00651118
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02025634
Drug: Intravenous Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to intravenous acetaminophen (Ofirmev) will receive an infusion of Ofirmev in 100 ml of 0.9 NS according to manufacturer's recommendations related to subject's weight.
Study: NCT02025634
Drug: Placebo (0.9% Normal Saline infusion)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 100 ml of 0.9% NS
Study: NCT00649285
Drug: Macrobid® Capsules 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg, single dose fed
Study: NCT01696799
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01844297
Drug: TDF+3TC+EFV
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04238091
Drug: Fecal material transfer therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota transplants will be performed as follows:~FMP Retention Enema: (FMP 250 mL) Dosage Form: Screened human donor stool, suspended in diluent of 12.5% glycerol and sterile normal saline buffer (0.9% NaCl) standardized to a 5X concentration (1g stool : 5mL diluent ratio), homogenized, filtered to 330 microns and aliquoted to sterile 250mL vessels.~Route of Administration: Fecal transplant will be performed under medical supervision. Lubricated enema tube will be inserted into rectum and contents expelled into the distal colon with the subject requested to retain material for a target dwell time of 3 to 24 hours with a mean target of 10 hours. Participants will lie in the left lateral decubitus position but if mobility permits will rotate to supine and right lateral decubitus position.~One half of study subjects will receive a 3 day course of antibiotics prior to fecal transplant, while the other half will not.
Study: NCT04238091
Drug: Pre-FMT Antibiotic Cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: For three days prior to the transplant, one half (20) of the subjects enrolled will be treated with antibiotics to reduce the burden of the existing microbiome. The antibiotic regimen will consist of: oral vancomycin 250 mg qid, ciprofloxacin 500 mg bid, and metronidazole 500 mg tid. For subjects who have antibiotic allergies, appropriate antibiotic substitutions will be made. Subjects will stop the antibiotics 48 hours before the fecal transplant.
Study: NCT04238091
Drug: Bowel Prep
Normalized name: Suprep Bowel Prep Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: The night before the transplant, all enrolled subjects will take 20 mg of bisacodyl and a large volume bowel preparation (GoLyteley 4000cc). Fecal transplant will be performed under medical supervision. After the transplant, subjects will take 4 mg of loperamide to increase transplant retention.
Study: NCT03462641
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 cc normal saline
Study: NCT02443337
Drug: LY3023414
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00002509
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03849664
Drug: Cytoflavin® solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drip infusion of 20 ml of Cytoflavin® solution in 200 ml of 0.9%NaCl intravenously once a day
Study: NCT03849664
Drug: Cytoflavin® enteric-coated tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
Study: NCT03849664
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drip infusion of 20 ml of placebo solution in 200 ml of 0.9%NaCl intravenously once a day
Study: NCT03849664
Drug: Placebo enteric-coated tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets, orally, with 100 ml of drinking water, 30 minutes before meals, 2 times a day, with an interval of 8-10 hours (but no later than 18:00).
Study: NCT02819297
Drug: BLI400 Laxative
Normalized name: LAXATIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 gm BLI400 powder
Study: NCT02819297
Drug: BLI400 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equivalent amount of placebo powder
Study: NCT02317497
Drug: Vasopressors to maintain normal blood pressure values, if needed
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02317497
Drug: Osmotherapeutics to lowr intracranial pressure, if needed
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01927406
Drug: Prostaglandin Analog
Normalized name: Prostaglandin analog
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first choice drug from group of Prostaglandin Analogues will be bimatoprost, if patient will suffer from any side effect of this drug another drug from this group will be administer. If patient turned out to cannot tolerate the prostaglandin analog therapy then the exclusion criteria will be met.
Study: NCT01852942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet by mouth daily
Study: NCT00308503
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT01772303
Drug: HO/03/03 10-40 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: HO/03/03 10-40µg once daily (Topically) for up to 24 weeks.
Study: NCT03679780
Drug: NG Nitro L Arginine Methyl Ester
Normalized name: methyl L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
Study: NCT04283162
Drug: Calcium Dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: use calcium dobesilate at the dosage of 500 mg, orally, 3 times per day, for 12 months
Study: NCT00004733
Drug: levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04001881
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia is introduced with a single intrathecal injection of 12 to 18 mg (15 mg average dose) plain ropivacaine (0.75% solution) using a 22 or 25-gauge needle (pencil-point) with the patient in the lateral position.
Study: NCT02232425
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04782856
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: levothyroxine sodium tablet for oral use
Study: NCT04782856
Drug: Liothyronine
Normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liothyronine sodium tablets for oral use treatment of hypothyroidism
Study: NCT04782856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inert sugar tablets for oral use blinding for treatment of hypothyroidism
Study: NCT00138944
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: od
Study: NCT00138944
Drug: eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg od
Study: NCT03020823
Drug: SCB01A
Approvals — FDA: no, EMA: no, PMDA: no
Description: intra-subject dose escalation, 12, 18, 24 mg/m2, 24h-IV infusion (in the vein) on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT02631863
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with illumination
Study: NCT03911440
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral doxycycline is given with a dosage of 2-4 mg/kg/day divided into twice a day for 5-10 days.
Study: NCT03911440
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin is given with a dosage of 10 mg/kg/day once a day for 3 days.
Study: NCT01591291
Drug: Placebo + Brief Behavioral Enhancement Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily
Study: NCT02794896
Drug: High dose propofol, fentanyl and sevoflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep Anesthesia
Study: NCT02794896
Drug: Low dose propofol, fentanyl and sevoflurane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shallow Anesthesia
Study: NCT01843166
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2g at bedtime twice weekly
Study: NCT03860428
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the medical treatment arm the in-tention is to close the ductus arteriosus.
Study: NCT03715140
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02799758
Drug: Livalo® IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Livalo® IR 4 mg daily for 52 weeks
Study: NCT02799758
Drug: Placebo (for NK-104-CR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK-104-CR 8 mg placebo for 52 weeks
Study: NCT00644969
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomization 2:1 treatment to placebo
Study: NCT01020279
Drug: Celecoxib, Ketoprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen in Transfersome® gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d.~Celecoxib, 200 mg, one capsule b.i.d.
Study: NCT01020279
Drug: Ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d. Oral placebo, one capsule b.i.d
Study: NCT00697515
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered once-daily for one week during the adult workplace environment setting
Study: NCT00940212
Drug: AZD2423
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, single administration
Study: NCT00940212
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration and single dose
Study: NCT02436759
Drug: RVL-1201 Vehicle Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVL-1201 Vehicle Placebo
Study: NCT02292290
Drug: Sulfonylurea or Pioglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition to Metformin
Study: NCT03054857
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group received a loading dose and continuous IV infusion of normal saline at the same volume and rate as in the dexmedetomidine group
Study: NCT00146146
Drug: testosterone undecanoate alone
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000 mg/12 weeks
Study: NCT00146146
Drug: testosterone undecanoate plus letrozole
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TU 1000 mg/12 weeks Letrozole 2.5 mg/day
Study: NCT00146146
Drug: testosterone undecanoate plus dutasteride
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TU 1000 mg/12weeks Dutasteride 0.5 mg/day
Study: NCT00464568
Drug: GSK256066
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04231682
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of placebo in post liver transplant patient for prevention and management of osteoporosis and bone loss.
Study: NCT02397421
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing microcrystalline cellulose Ph Eur overencapsulated in a hard gelatine capsule shell to match the active comparator
Study: NCT00405587
Drug: PLX4032
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules administered BID
Study: NCT02419742
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AC-TH regimen: Cyclophosphamide 600 mg/m\^2 IV bolus every 3 weeks for 4 cycles (Cycles 1 to 4).
Study: NCT02419742
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive Doxorubicin 60 mg/m\^2 administered as I.V. bolus injection over 5 to 15 minute every 3 weeks for 4 cycles for AC-TH regimen.
Study: NCT00729027
Drug: 25 mg/day AVE5530
Approvals — FDA: no, EMA: no, PMDA: no
Description: * one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)
Study: NCT00729027
Drug: 50 mg/day AVE5530
Approvals — FDA: no, EMA: no, PMDA: no
Description: * one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)
Study: NCT00729027
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * one tablet in the evening with dinner~* in addition to statin treatment (HMG-CoA Reductase Inhibitors)
Study: NCT01411709
Drug: Vitano
Approvals — FDA: no, EMA: no, PMDA: no
Description: two 200mg tablets per day for 14 days
Study: NCT01404923
Drug: anti spasmodic agents
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: best standard of care prescriptions
Study: NCT03489772
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00684476
Drug: venom immunotherapy
Normalized name: bushmaster venom
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02905682
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03491995
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin, omeprazole sodium bicarbonate, nitazoxanide, doxycyclin
Study: NCT03491995
Drug: Classic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, amoxycillin, clarithromycin
Study: NCT00523250
Drug: AR-102 0.003% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00523250
Drug: AR-102 0.005% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00523250
Drug: AR-102 0.01% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00617097
Drug: ketorolac and lidocaine
Normalized name: phenylephrine and ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: paracervical block with ketorolac and lidocaine
Study: NCT00523250
Drug: AR-102 0.03% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03060993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be administered placebo (cannabis stripped of cannabinoids) in vaporized form.
Study: NCT03083665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Pharmaceutical form: Film-coated tablets~* Route of administration: Oral use
Study: NCT00140153
Drug: testosterone gel (Androgel)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02565147
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin is an anticoagulant.
Study: NCT01142310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01275274
Drug: Standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone. Dose, frequency and duration depend on disease activity (partial or complete remission).
Study: NCT01153243
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigators will give control group 12 weeks of 1 placebo pill every week.
Study: NCT02177448
Drug: BIBR277 medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02177448
Drug: Placebo matching BIBR277
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01008761
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days Each syringe will contain 12.5 mls (250 mgs) sufficient drug to adequately dose children who with up to 25 kgs (95%tile for weight for 60 month old child)
Study: NCT01324388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously
Study: NCT03837561
Drug: Cunox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inject 4 Units (0.1 mL) of reconstituted investigational product or the comparator intramuscularly into each of 5 sites, 2 in each corrugator muscle and 1 in the procerus muscle for a total dose of 20 Units.
Study: NCT01008761
Drug: Suspension Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suspension will be administered on day 1 at 10mg/kg and then for the next 4 days at 5 mg/kg
Study: NCT01085097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to laquinimod will be administered per schedule specified in the arm description.
Study: NCT03149107
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM).
Study: NCT03384329
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Pills
Study: NCT03345589
Drug: 18-22mg/kg/d Ursodeoxycholic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18-22mg/kg/d Ursodeoxycholic
Study: NCT03345589
Drug: 13-15mg/kg/d Ursodeoxycholic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-15mg/kg/d Ursodeoxycholic
Study: NCT03963115
Drug: Epinephrine or normal saline
Normalized name: Rosula NS Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: epinephreine or normal saline coated syringe before drawing allergen for injection.
Study: NCT00780325
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib (Celebrex®) capsules: 200 mg; single oral administration (Part 1 and 3)
Study: NCT00780325
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules: 198 mg silicified microcrystalline cellulose + 2 mg talc, multiple oral administrations (Part 1 and 3)
Study: NCT00780325
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen (Naprosyn®) tablets: 500 mg, single oral administration (Part 3)
Study: NCT04225299
Drug: TOOKAD®
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOOKAD® -VTP procedure will consist of an IntraVenous (IV) administration to patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance
Study: NCT00124969
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg
Study: NCT01147705
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same appearance/dosing as active drug.
Study: NCT01708174
Drug: LDE225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonidegib for oral suspension was supplied in amber glass bottles. Sonidegib oral suspension was combined with the supplied reconstitution vehicle to a final concentration of 50 mg/mL.